Sponsor Deadline
Posted: 4/18/2022

Cellular Senescence Network: Technology Development and Application in Murine Systems (UG3/UH3 Clinical Trial Not Allowed)

The purpose of this FOA is to solicit novel analytics and technologies to identify and map senescent cells in murine tissues at high resolution. This FOA supports the accelerated proof-of-principle demonstration of promising tools, techniques and methods that can be integrated, scaled, and applied to multiple murine tissues. The initial two-year UG3 phase will support the development and demonstration of feasibility of these emerging technologies in the identification and mapping of senescent cells in murine tissues. The subsequent UH3 phase is to support initial validation in multiple murine and/or human tissues, optimization and scale-up, generation of production level data and the application of the technology to describe cellular senescence in a mouse life course situation (for example development or lifespan). Investigators responding to this FOA must submit both UG3 and UH3 projects as part of a single application. UG3 projects that have met their quantifiable milestones will be administratively considered by NIH staff and prioritized for transition to the UH3 phase, depending on the availability of funds.

These efforts related to murine cellular senescence will be funded by this, and a second FOA, RFA-RM-22-003, through which the mTMCs will be funded. A third SenNet FOA, RFA-RM-22-004, accompanies these FOAs, to fund additional Technology Development and Application Projects in human tissues.


  • Letter of Intent Due Date(s): Dec. 20, 2021

  • Application Due Date(s): Jan. 19, 2022

RFA-RM-22-005 Expiration Date January 20, 2022

Eligibility Requirements

An investigator designated as the Contact PD/PI or MPI of an application under this FOA must not be the designated Contact PD/PI of any currently funded RFA-RM-21-008; RFA-RM-21-009, RFA-RM-21-010 or any of the companion SenNet FOAs RFA-RM-22-003 and RFA-RM-22-004.

Amount Description

Application budgets are not limited but must reflect the actual needs of the proposed project. Applications should not exceed $350,000 in direct costs per year during the UG3 phase and $500,000 in direct costs per year during the UH3 phase.